ライフサイエンスコーパス: heparin-binding EGF-like growth factor

1 ptor via activation of the endogenous ligand heparin-binding EGF-like growth factor.

2 y neuregulins (NRG), betacellulin (BTC), and heparin-binding EGF-like growth factor.

3 TC, and to a lesser extent by NRG-alpha1 and heparin-binding EGF-like growth factor.

4 l growth factor (EGF) receptor (EGFR) ligand heparin-binding EGF-like growth factor.

5 (EGF), transforming growth factor alpha, or heparin-binding EGF-like growth factor].

6 ing growth factor-alpha (14.4 +/- 5.0-fold), heparin-binding EGF-like growth factor (4.5 +/- 1.4-fold

7 uding EGF, transforming growth factor alpha, heparin-binding EGF-like growth factor, amphiregulin, ep

8 that key markers of implantation, including Heparin binding EGF-like growth factor and Mucin 1, exhi

9 Whereas heparin-binding EGF-like growth factor and antioxidant N

10 or endothelin-1, smooth muscle growth factor heparin-binding EGF-like growth factor, and fatty acid b

11 EGFR but not the 145-kDa EGFR, whereas EGF, heparin-binding EGF-like growth factor, and transforming

12 ated 14,15-EET stimulates release of soluble heparin-binding EGF-like growth factor as an EGFR ligand

13 We identified fibronectin, collagen, and heparin-binding EGF-like growth factor as embryonic card

14 sed levels of output of free fatty acids and heparin-binding EGF-like growth factor from the adipose

15 onses in skin epidermis through secretion of heparin-binding EGF-like growth factor, GM-CSF, IL-1alph

16 in and metalloprotease) 17 and 19 as well as heparin binding EGF-like growth factor (HB-EGF) and neur

17 (3) A neutralizing antibody that recognizes heparin binding EGF-like growth factor (HB-EGF) blocked

18 A competitive antagonist (P22) for heparin binding EGF-like growth factor (HB-EGF) blocked

19 Recent studies have demonstrated that heparin binding EGF-like growth factor (HB-EGF) expressi

20 Heparin binding EGF-like growth factor (HB-EGF), encoded

21 the second had the corresponding domain from heparin binding EGF-like growth factor (HB-EGF).

22 n elicits expression of cytokines, including heparin binding-EGF-like growth factor (HB-EGF), that up

23 igen stimulation increased the expression of heparin-binding EGF-like growth factor (HB-EGF) and acti

24 ptor, EGF, transforming growth factor-alpha, heparin-binding EGF-like growth factor (HB-EGF) and amph

25 ng a metalloprotease-dependent generation of heparin-binding EGF-like growth factor (HB-EGF) and prot

26 x metalloproteinase inhibitor (GM6001), or a heparin-binding EGF-like growth factor (HB-EGF) antagoni

27 tide 3-kinase (PI3K) inhibitor LY294002, the heparin-binding EGF-like growth factor (HB-EGF) antagoni

28 forming growth factor-alpha (TGF-alpha), and heparin-binding EGF-like growth factor (HB-EGF) are thou

29 infection, the EGFR ligands amphiregulin and heparin-binding EGF-like growth factor (HB-EGF) are upre

30 receptor (EGFR) via a pathway that involves heparin-binding EGF-like growth factor (HB-EGF) as ligan

31 leased to be active, whereas others, such as heparin-binding EGF-like growth factor (HB-EGF) can func

32 ce, we show here that maternal deficiency of heparin-binding EGF-like growth factor (HB-EGF) defers o

33 Ang II elicited release of soluble heparin-binding EGF-like growth factor (HB-EGF) from AT1

34 tinib stimulated shedding of the EGFR ligand heparin-binding EGF-like growth factor (HB-EGF) from HNS

35 Here we show a novel role for heparin-binding EGF-like growth factor (HB-EGF) in the d

36 Wounding, lysophosphatidic acid, and heparin-binding EGF-like growth factor (HB-EGF) induced

37 pon amphiregulin (AREG), whereas blockade of heparin-binding EGF-like growth factor (HB-EGF) inhibits

38 s studies established that the gene encoding heparin-binding EGF-like growth factor (HB-EGF) is expre

39 Heparin-binding EGF-like growth factor (HB-EGF) is expre

40 We have previously shown that heparin-binding EGF-like growth factor (HB-EGF) is induc

41 (E) 19 fetal type II cells with recombinant heparin-binding EGF-like growth factor (HB-EGF) or trans

42 Silencing of the miR-132 target heparin-binding EGF-like growth factor (HB-EGF) phenocop

43 Heparin-binding EGF-like growth factor (HB-EGF) shedding

44 Epidermal growth factor (EGF) and heparin-binding EGF-like growth factor (HB-EGF) strongly

45 Amphiregulin and heparin-binding EGF-like growth factor (HB-EGF) transcri

46 rformed a microarray assay and observed that heparin-binding EGF-like growth factor (HB-EGF) was sign

47 scripts for TGFalpha, amphiregulin (AR), and heparin-binding EGF-like growth factor (HB-EGF) were ind

48 eloping extravillous trophoblasts accumulate heparin-binding EGF-like growth factor (HB-EGF), a multi

49 Here we show that heparin-binding EGF-like growth factor (HB-EGF), an acti

50 , TGF-alpha (TGFalpha), amphiregulin (AREG), heparin-binding EGF-like growth factor (HB-EGF), betacel

51 genic mice that express the ligand for EGFR, Heparin-binding EGF-like growth factor (HB-EGF), in the

52 The EGFR ligand, heparin-binding EGF-like growth factor (HB-EGF), is synt

53 ng the epidermal growth factor (EGF) ligands heparin-binding EGF-like growth factor (HB-EGF), neuregu

54 platelet-derived growth factor (PDGF)-BB, or heparin-binding EGF-like growth factor (HB-EGF), we show

55 dendritic cells (TADCs) production of mature heparin-binding EGF-like growth factor (HB-EGF), which,

56 ceptor (EGFR) through ectodomain shedding of heparin-binding EGF-like growth factor (HB-EGF).

57 o heal in the presence or absence of HGF and heparin-binding EGF-like growth factor (HB-EGF).

58 rothelial cell growth factor and EGFR ligand heparin-binding EGF-like growth factor (HB-EGF).

59 f the Src family kinases PP2 and EGFR ligand heparin-binding EGF-like growth factor (HB-EGF).

60 rotein-coupled receptor agonists can involve heparin-binding EGF-like growth factor (HB-EGF).

61 ancer: fibroblast growth factor 2 (FGF2) and heparin-binding EGF-like growth factor (HB-EGF).

62 er of ligands at the EGF receptor TGF-alpha; heparin-binding EGF-like growth factor (HB-EGF); and amp

63 d to, basic fibroblast growth factor (FGF2), heparin-binding EGF-like growth factor (HBEGF), vascular

64 Heparin-binding EGF-like growth factor (HBEGF), which is

65 electively expressing the EGFR ligand, human heparin-binding EGF-like growth factor (hHB-EGF), in ren

66 nic effect in combination with either EGF or heparin-binding EGF-like growth factor in the RASM cells

67 rming growth factor alpha, amphiregulin, and heparin-binding EGF-like growth factor in these cells.

68 We report here that IP-10 inhibited EGF- and heparin-binding EGF-like growth factor-induced Hs68 huma

69 tested (i.e., epidermal growth factor [EGF], heparin-binding EGF-like growth factor, interleukin 6, a

70 n kinase activity, and downregulated HB-EGF (heparin-binding EGF-like growth factor) mRNA levels.

71 activator inhibitor 2 (SERPINB5; 4.6-fold), heparin-binding EGF-like growth factor precursor (DTR; 4

72 ccurred in an autocrine manner downstream of heparin-binding EGF-like growth factor precursor cleavag

73 ributed specifically to the membrane form of heparin-binding EGF-like growth factor (proHB-EGF), rath

74 Blocking Abs against the EGFR or against heparin-binding EGF-like growth factor similarly blocked

75 Accordingly, addition of soluble heparin-binding EGF-like growth factor to Jag1-mutant ou

76 ve assays, we found significant increases of heparin-binding EGF-like growth factor, transforming gro